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Abstract
Background
The ColonCancerCheck screening program for colorectal cancer (CRC) in Ontario, Canada,
is considering switching from biennial guaiac fecal occult blood test (gFOBT) screening
between age 50–74 years to the more sensitive, but also less specific fecal immunochemi-
cal test (FIT). The aim of this study is to estimate whether the additional benefits of FIT
screening compared to gFOBT outweigh the additional costs and harms.
Methods
We used microsimulation modeling to estimate quality adjusted life years (QALYs) gained
and costs of gFOBT and FIT, compared to no screening, in a cohort of screening partici-
pants. We compared strategies with various age ranges, screening intervals, and cut-off
levels for FIT. Cost-efficient strategies were determined for various levels of available colo-
noscopy capacity.
Results
Compared to no screening, biennial gFOBT screening between age 50–74 years provided
20 QALYs at a cost of CAN$200,900 per 1,000 participants, and required 17 colonoscopies
per 1,000 participants per year. FIT screening was more effective and less costly. For the
same level of colonoscopy requirement, biennial FIT (with a high cut-off level of 200 ng Hb/
ml) between age 50–74 years provided 11 extra QALYs gained while saving CAN$333,300
per 1000 participants, compared to gFOBT. Without restrictions in colonoscopy capacity,
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FIT (with a low cut-off level of 50 ng Hb/ml) every year between age 45–80 years was the
most cost-effective strategy providing 27 extra QALYs gained per 1000 participants, while
saving CAN$448,300.
Interpretation
Compared to gFOBT screening, switching to FIT at a high cut-off level could increase the
health benefits of a CRC screening program without considerably increasing colonoscopy
demand.
Introduction
In most developed countries, including Canada, colorectal cancer (CRC) is the second leading
cause of cancer deaths and the third most commonly diagnosed cancer.[1, 2] Screening for
CRC and its precursor lesions, adenomas, can detect colorectal neoplasia at an earlier stage
when treatment is potentially more effective, resulting in reduced CRC incidence and mortal-
ity.[3, 4]
Like a number of regions around the world,[5, 6] the province-wide ColonCancerCheck
screening program in Ontario, uses the guaiac fecal occult blood test (gFOBT) to screen indi-
viduals at average risk of CRC.[7] Fecal immunochemical testing (FIT) offers several advan-
tages over gFOBT, including greater sensitivity, no need for dietary restrictions and automated
processing of test kits.[8] However, depending on the cut-off level used FIT also has a lower
specificity, which is associated with increased colonoscopy demand.
At the time of the funding announcement and public launch of the ColonCancerCheck
program, the evidence base to support FIT was increasing, but FIT was not yet endorsed by
the Canadian Task Force on Preventive Health Care.[9] Hence the implementation of gFOBT
by the program. Currently the evidence base has increased sufficiently for the program to con-
sider replacing the gFOBT with FIT as the screening test. In order to inform this decision, the
aim of the present study is to compare the costs and benefits of gFOBT and FIT screening in
average risk individuals.
Methods
We used the MISCAN-Colon microsimulation model to estimate the quality adjusted life
years (QALYs) gained and costs of gFOBT and FIT screening with varying screening age
ranges and intervals, and various FIT cut-off levels in a cohort of average risk Ontarians. Cost-
efficient strategies were determined for different levels of available colonoscopy capacity.
MISCAN-colon microsimulation model
The MISCAN-colon model and the data sources that inform the quantifications of the model
are described in detail in S1 Appendix and in previous publications.[10–12] In brief, the MIS-
CAN-colon model simulates the life histories of individuals from birth to death. CRC arises in
the population according to the adenoma-carcinoma sequence.[13, 14] More than one ade-
noma can occur in an individual and each adenoma can independently develop into CRC.
Adenomas can progress in size from small (5 mm) to medium (6–9 mm) to large (10 mm),
and some may eventually become malignant. A preclinical (i.e., not detected) cancer has a
chance of progressing through stages I to IV and may be detected by diagnostic work-up of
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symptoms at any stage. After the diagnosis of CRC, survival depends on the stage at diagnosis.
At any time during their life individuals may die of other causes.
With screening, an individual with a positive test will be referred for diagnostic colonos-
copy for possible removal of adenomas and detection of cancers. In this way CRC incidence
and mortality can be reduced. The life years gained (LYG) by screening are calculated as the
difference in model-predicted life years lived in the population with and without CRC
screening.
The validity of the MISCAN-colon model has been successfully tested on the results of large
screening and surveillance studies, such as the randomized trials of gFOBT in Minnesota,
Funen, and Nottingham,[12] the CoCap sigmoidoscopy study,[15] and the National Polyp
Study.[16] In addition, the model was able to explain observed CRC incidence and mortality
trends in the United States when accounting for risk factor trends, screening practice, and che-
motherapy.[17] For FIT screening, the simulated stage distribution of screen-detected cancers
and the simulated mortality effects were consistent with data from population-based studies.
[18, 19] In addition, model-predicted adenoma and cancer detection rates for different cut-off
values of FIT showed good concordance with rates observed in Dutch pilot studies (S1 Table).
Study population
We modeled a cohort of 40-year-old screening participants at average risk of CRC which was
followed until death. The CRC incidence and stage distribution were calibrated to incidence
data from the Canadian Cancer Registry for 2001, which was prior to the introduction of
screening.[20] The model used all-cause mortality estimates from the 2009–2011 Ontario life
tables.[21] Because stage-specific data on CRC relative survival were not available for Canada,
we assumed similar relative survival as observed in the Surveillance, Epidemiology, and End-
Results (SEER) database in the US, in the period 2000–2003.[22]
Screening strategies
We considered screening strategies for both gFOBT and FIT varying by age of starting screen-
ing (40, 45, 50, 55, 60 or 65 years), age of stopping screening (70, 75, 80 or 85 years), screening
interval (1, 1.5, 2, or 3 years), and FIT cut-off level used to define a positive test result (50, 75,
100, 150 and 200 ng Hb/ml). The combinations of these variables resulted in 576 unique
screening strategies. We used common random numbers for the simulation of every screening
strategy to reduce differences in outcomes between strategies due to random variability.
After a positive test result individuals were referred for diagnostic colonoscopy. Depending
on the number and size of adenomas detected, the individual would be recommended for sur-
veillance colonoscopy based on current guidelines.[23]
Test characteristics
The test characteristics of gFOBT were based on a prior calibration of the MISCAN-Colon
model to three large gFOBT trials (Table 1).[12] It was assumed that, the probability a CRC
bleeds and thus the sensitivity of gFOBT for CRC depends on the time to clinical diagnosis, i.e.
cancers that bleed do so increasingly over time, starting in occult fashion and progressing to
grossly visible bleeding. The test characteristics of FIT (OC-Sensor Micro; Eiken Chemical Co,
Tokyo, Japan) were fitted to the FIT positivity rates and detection rates of adenomas and CRC
observed in the first screening round of two Dutch randomized trials.[24–26] We considered
FIT cut-off levels of 50, 75, 100, 150 and 200 ng Hb/ml, yielding different combinations of sen-
sitivity and specificity. The test characteristics of colonoscopy were based on a systematic
review of polyp miss rates in tandem colonoscopy studies.[27] The lack of specificity of
Cost-effectiveness of FIT versus gFOBT screening
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colonoscopy reflects the detection of hyperplastic polyps, which are not explicitly simulated in
the MISCAN-Colon model.[28] Additional biopsy costs were assumed for procedures where
biopsies were performed and in which, in retrospect, no adenomas were detected.
Health-related quality of life
Health benefits were expressed in quality adjusted life years (QALYs) gained. In the model,
health-related quality of life declines with increasing age based on a large longitudinal study on
the quality of life of Canadians.[29] We incorporated utility losses associated with colonoscopy
and its associated complications and CRC using a multiplicative approach (Table 2). Losses in
health utility (i.e. loss of quality of life) associated with CRC were based on a recent literature
review (Table 2).[30] We assumed a utility loss equivalent to 2 days of life per colonoscopy per-
formed (0.0055 QALYs), and 2 weeks of life for non-lethal complications (0.0384 QALYs).
Costs
The analysis was conducted from a third party health-care payer perspective. All costs were
expressed in 2013 Canadian dollars (Table 3). The cost of gFOBT included costs of test kit, dis-
pensing fee, postage, lab processing, communicating results to the participants and collecting
data for the screening registry, and was obtained from the ColonCancerCheck program. Since
FIT is currently not funded in Ontario, the costs of test kit and processing are unknown.
Therefore we estimated the costs of FIT test kit and processing based on the difference between
gFOBT and FIT in a Dutch screening trial[31, 32], and applied this difference to the cost of
gFOBT in Ontario. We assumed that the dispensing fee and communication of the test results
would be identical to gFOBT. The costs attributable to CRC care by CRC stage and phase of
care (initial, continuing, and terminal care) included outpatient visits, hospitalizations, treat-
ment, home care, long-term care, and rehabilitation. The costs were estimated using health
care administrative data in a matched cohort study, which compared the health care costs of
CRC patients with their age- and sex-matched controls (manuscript in preparation).
Table 1. Test characteristics of the screening tests used in the model.
Screen test Specificity (%) Sensitivity* (%)
Adenoma CRC
Small (5mm) Medium (6-9mm) Large (10mm) Early preclinical† Late preclinical† Average
gFOBT 98 2 3 8 20 52 33
FIT 50 96 4 15 37 52 83 65
FIT 75 97 3 9 31 48 81 62
FIT 100 98 2 7 28 43 77 57
FIT 150 98 2 5 25 41 76 56
FIT 200 99 1 4 21 40 76 55
Colonoscopy‡ 90 75 85 95 95 95 95
CRC, colorectal cancer; gFOBT, guaiac fecal occult blood test; FIT, fecal immunochemical test.
* Sensitivity is presented per participant for fecal occult blood tests and per lesion for colonoscopy.
† It was assumed that the probability a CRC bleeds and thus the sensitivity of gFOBT and FIT for CRC depend on the time to clinical diagnosis, based on a
prior calibration of the MISCAN-Colon model to three gFOBT trials.[12] This result is to be expected when cancers that bleed do so increasingly over time,
starting in occult fashion and progressing to grossly visible bleeding.
‡ Colonoscopy was only used during follow-up and surveillance after a positive gFOBT or FIT. The lack of specificity of colonoscopy reflects the detection of
hyperplastic polyps, which are not explicitly simulated by the MISCAN-Colon model.[28] Additional biopsy costs were assumed for procedures where
biopsies were performed and in which, in retrospect, no adenomas were detected.
https://doi.org/10.1371/journal.pone.0172864.t001
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Cost-effectiveness analyses
For each screening strategy we estimated the number of QALYs gained and costs, compared to
no screening. Strategies that were more costly and less effective than other strategies were
ruled out by simple dominance. Strategies that were more costly and less effective than a mix
of other strategies were ruled out by extended dominance. The remaining strategies that were
not ruled out were referred to as “efficient” strategies. The incremental cost-effectiveness ratio
(ICER) of an efficient strategy was determined by comparing its additional costs and health
benefits to those of the next less costly and less effective efficient strategy.
Sensitivity analyses
We performed several sensitivity analyses assuming: 1) dependency of test results between
screening rounds (74% of large adenomas could not be detected because they did not bleed
[33]); 2) half and double the base case rate of colonoscopy complications; 3) 25% increased
CRC relative survival; 4) FIT unit costs of 43.87 CAN$ (based on the difference in reimburse-
ment rate between FIT and gFOBT in the US Medicare program[34]); 5) half and double the
base case value for colonoscopy costs; 6) half and double the base case value for CRC treatment
costs.
Outcomes
The main outcomes of the analysis were QALYs and costs per 1,000 participants, and number
of colonoscopies per 1,000 participants per year, compared to no screening. Costs and QALYs
were discounted by 3% per year[35], the number of colonoscopies were undiscounted.
Table 2. Utility weights used in the model.
Variable Utility loss
Screening, per event
gFOBT -
FIT -
Colonoscopy, no polypectomy 0.0055
Colonoscopy, polypectomy 0.0055
Complication, bleeding* 0.0384
Complication, perforation* 0.0384
Treatment, per person year of CRC care[30]† Initial care Continuous care Terminal care, death CRC Terminal care, death other causes
Stage I 0.15 0.10 0.29 0.10
Stage II 0.15 0.10 0.29 0.10
Stage III 0.15 0.10 0.29 0.10
Stage IV 0.34 0.29 0.29 0.29
gFOBT: guaiac fecal occult blood test; FIT: fecal immunochemical test; CRC: colorectal cancer.
*We assumed a utility loss equivalent to 2 days of life per colonoscopy performed (0.0055 QALYs) and 2 weeks of life for non-lethal complications (0.0384
QALYs). We assumed complications with bleeding in 1.64 per 1,000 procedures, and complications with perforation in 0.85 per 1,000 procedures. In
addition, we assumed 1/14,000 colonoscopies resulted in fatal complications.
† CRC treatments were divided into three clinically relevant phases—initial, continuous and terminal care. The initial phase was defined as the first 12
months following diagnosis, the terminal phase was defined as the final 12 months of life, and the continuous phase was defined as all months between the
initial and terminal phase. For patients surviving less than 24 months, the final 12 months were allocated to the terminal phase. The remaining months of
observation were allocated to the initial phase.
https://doi.org/10.1371/journal.pone.0172864.t002
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Results
The current screening strategy in Ontario, biennial gFOBT between age 50–74 years, yielded
20 QALYs at a cost of CAN$220,900 per 1,000 screening participants, compared to no screen-
ing (Fig 1). When colonoscopy capacity is not a limiting factor, increasing the screening age
range to 40–85 years with annual gFOBT could provide a maximum of 37 QALYs at a cost of
CAN$507,000 per 1,000 participants. For each gFOBT screening strategy there was a FIT strat-
egy that provided more QALYs at lower costs, therefore FIT dominated gFOBT. The FIT strat-
egies on the efficient frontier provided 34 to 51 QALYs, at a cost of -CAN$354,200 to -CAN
$48,000 per 1,000 participants, compared to no screening. Assuming a willingness-to-pay
threshold of CAN$50,000 per QALY gained, FIT every year between age 45–80 years would be
the preferred strategy, providing 49 QALYs per 1,000 participants.
With unrestricted colonoscopy capacity almost all cost-effective strategies used FIT with a
cut-off level of 50 ng Hb/ml (Table 4, see Table 5 for intermediate outcomes). The number of
colonoscopies required for the strategies on the efficient frontier ranged from 32 to 69 per
1,000 participants per year. This is a two- to four-fold increase over the colonoscopy demand
of the current screening strategy in Ontario (17 colonoscopies per 1,000 participants per year).
Table 3. Cost estimates used in the model (2013 Canadian dollars).
Variable Cost (CAN$) Source
Fixed program costs per year
(assumed identical for gFOBT and FIT
screening)
Year 1: 6,592,000, Year 2: 15,151,000, Year 3: 13,536,000,
Year 4: 10,876,000, Year 5: 11,071,000, Year 6+: 10,652,000
ColonCancerCheck program*
Screening, per event
gFOBT 28.23 ColonCancerCheck program*
FIT† 31.11 ColonCancerCheck program*, [31, 32]
GP visit after positive stool test 34.73 [46]
Colonoscopy, no polypectomy 872 [46, 47]
Colonoscopy, polypectomy 1,097 [46, 47]
Complication, bleeding‡ 3,521 [45, 48]
Complication, perforation‡ 34,412 [45, 48]
Treatment, per person year of CRC
care§
Initial
care
Continuous
care
Terminal care,
death CRC
Terminal care,
death other
causes
Stage I 28,981 7,442 302,484 29,780 Matched cohort study using health care
administrative data (manuscript in
preparation)Stage II 43,348 10,435 202,540 37,411Stage III 62,259 13,344 134,354 31,334
Stage IV 83,440 42,551 117,128 29,328
gFOBT: guaiac fecal occult blood test; FIT: fecal immunochemical test; GP: general practitioner; CRC: colorectal cancer.
* The fixed program costs include costs for the screening registry, program infrastructure, communications and advertising, and sending activity reports to
primary care physicians. Personal communication with co-author Dr. Linda Rabeneck, Vice President Prevention and Cancer Control at Cancer Care
Ontario.
† FIT is currently not funded in Ontario, therefore the costs of test kit and processing are unknown. We estimated the costs of FIT test kit and processing
based on the difference between gFOBT and FIT in a Dutch screening trial, and applied this difference to the cost of gFOBT in Ontario.
‡ We assumed complications with bleeding in 1.64 per 1,000 procedures, and complications with perforation in 0.85 per 1,000 procedures. In addition, we
assumed 1/14,000 colonoscopies resulted in fatal complications.
§ CRC treatments were divided into three clinically relevant phases—initial, continuous and terminal care. The initial phase was defined as the first 12
months following diagnosis, the terminal phase was defined as the final 12 months of life, and the continuous phase was defined as all months between the
initial and terminal phase. For patients surviving less than 24 months, the final 12 months were allocated to the terminal phase. The remaining months of
observation were allocated to the initial phase.
https://doi.org/10.1371/journal.pone.0172864.t003
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However, when colonoscopy capacity was restricted to 40, 30, 20, or 17 colonoscopies per year
FIT remained more cost-effective than gFOBT. At 17 colonoscopies per 1,000 participants per
year, biennial FIT with a cut-off level of 200 ng Hb/ml, between age 50–74 years still provided
31 QALYs at a cost of -CAN$73,200, compared to 20 QALYs at a cost of CAN$220,900 for
gFOBT (Fig 2).
Sensitivity analyses
The more favorable cost-effectiveness of FIT compared to gFOBT screening strategies was
robust to alterations in our model assumptions. None of the sensitivity analyses resulted in a
gFOBT strategy on the efficient frontier (S2 Table). Varying colonoscopy and treatment costs
had the largest impact on cost-effectiveness.
Interpretation
Our study shows that compared to the current CRC screening strategy in Ontario (biennial
gFOBT between age 50–74 years), replacing gFOBT by FIT with a cut-off level of 200 ng Hb/ml
provides more QALYs at lower costs, without increasing the number of colonoscopies required.
If the colonoscopy capacity were expanded greater health benefits and cost-reductions could be
achieved by lowering the FIT cut-off level and shortening the screening interval from biennial
Fig 1. Discounted total costs and discounted QALYs gained, per 1,000 participants, of the gFOBT and FIT
screening strategies compared to no screening. QALY: quality adjusted life year; gFOBT: guaiac fecal occult blood
test; FIT: fecal immunochemical test. Current screening strategy in Ontario: biennial gFOBT, between age 50–74.
Strategies are varied by age at starting screening, age at stopping screening, screening interval, and FIT cut-off level.
The cost-effective strategies are connected by the efficient frontier. Costs (expressed in 2013 Canadian dollars) and
QALYs are discounted by 3% per year.
https://doi.org/10.1371/journal.pone.0172864.g001
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to annual. Without restriction in colonoscopy capacity and assuming a willingness-to-pay
threshold of CAN$50,000 per QALY, FIT at a cut-off of 50 ng/ml between age 40–80 years with
a 1 year interval was the most effective strategy providing 47 QALYs compared to no screening.
The fact that screening FIT is less costly than gFOBT (and even cost-saving compared to no
screening) results from the combination of increased sensitivity for adenomas and high costs
Table 4. Overview of the current gFOBT screening strategy in Ontario, and efficient FIT screening strategies, compared to no screening*. Out-
comes per 1,000 participants.
Screen test Start age (years) Stop age (years)† Interval (years) Col/year (N) QALYs (years) Costs (CAN$) ICER (CAN$)
Current screening strategy in Ontario
gFOBT 50 75 2 16.9 20.3 220,915 dominated
Cost-effective screening strategies
Unrestricted colonoscopy capacity
FIT 50 55 75 1.5 31.6 33.8 -354,200 -10,500
FIT 50 50 80 1.5 40.9 41.8 -354,200 0
FIT 50 50 80 1 49.4 44.0 -325,600 13,000
FIT 50 45 80 1.5 48.8 46.5 -283,100 17,400
FIT 50 45 80 1 58.6 48.8 -195,600 37,800
FIT 50 40 80 1 68.7 51.3 44,300 95,100
FIT 50 40 85 1 69.1 51.3 48,000 132,300
Maximal 40 colonoscopies per 1,000 participants per year
FIT 50 55 75 1.5 31.6 33.8 -354,200 -10,500
FIT 50 50 75 1.5 39.3 41.3 -353,900 5,000
FIT 75 45 75 1.5 39.2 44.0 -226,200 47,100
FIT 100 45 70 1 39.4 45.1 -171,300 52,600
FIT 150 45 80 1 36.2 45.5 -147,100 55,500
FIT 200 40 80 1 36.8 47.9 39,400 79,300
FIT 200 40 85 1 37.3 48.0 55,100 144,200
Maximal 30 colonoscopies per 1,000 participants per year
FIT 50 55 70 1.5 29.1 32.6 -333,800 -10,200
FIT 75 50 70 1.5 29.9 37.8 -267,200 12,800
FIT 150 50 75 1 29.1 40.0 -228.300 17,900
FIT 200 45 70 1 28.4 42.2 -87,400 65,100
FIT 200 40 85 1.5 29.3 42.6 43,400 33,500
Maximal 20 colonoscopies per 1,000 participants per year
FIT 50 60 75 3 19.9 27.0 -252,100 -9,300
FIT 200 50 75 1.5 19.6 34.3 -121,700 18,000
FIT 200 45 75 2 19.9 35.0 -45,100 107,900
Maximal 17 colonoscopies per 1,000 participants per year
FIT 50 60 75 3 16.8 21.5 -185,800 -8,600
FIT 100 55 70 2 16.2 25.8 -164,800 4,800
FIT 150 55 70 1.5 16.5 27.6 -150,600 7,900
FIT 200 50 75 2 16.4 30.9 -73,200 23,700
Col/year: number of colonoscopies required per 1,000 participants per year; QALY: quality adjusted life year gained; ICER: incremental cost-effectiveness
ratio. The number of colonoscopies per year are undiscounted. Costs and QALYs are discounted by 3% per year.
* Without screening, costs for management of CRC amount to $5.2 million and total QALY in the population in the cohort to 23 thousand QALY.
† Stop age of screening is not necessarily the age of last screening. The last age of screening depends on start age and interval and is the latest age that
can be acquired with that start age and interval that still is below the stop age of screening. For example, screening every 1.5 years from age 55 results in a
final screening to be performed at the age of 74.5 years.
https://doi.org/10.1371/journal.pone.0172864.t004
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Table 5. Undiscounted intermediate model outcomes per 1,000 participants, compared to no screening.
Screen test (age range, interval) Total tests (N) Positive tests (N) Col/year (N) CRC cases (N) CRC deaths (N) LYG (years) QALYs (years)
Current screening strategy in Ontario
gFOBT (50–74, 2) 10346 258 16.9 -12.6 -10.8 122.5 65.2
Cost-effective screening strategies (unrestricted colonoscopy capacity)
FIT 50 (55–74.5, 1.5) 8989 491 31.6 -28.4 -17.9 194.0 109.3
FIT 50 (50–80, 1.5) 11695 609 40.9 -32.6 -20.2 225.8 130.3
FIT 50 (50–80, 1) 14563 725 49.4 -35.6 -20.9 235.4 136.8
FIT 50 (45–79.5, 1.5) 13094 659 48.8 -34.3 -20.7 240.6 141.5
FIT 50 (45–80, 1) 16107 779 58.6 -37.3 -21.6 250.9 148.3
FIT 50 (40–80, 1) 17441 822 68.7 -38.6 -22.0 260.5 154.8
FIT 50 (40–85, 1) 17791 839 69.1 -38.9 -22.2 261.4 154.9
Col/year: number of colonoscopies required per 1,000 participants per year; CRC: colorectal cancer; LYG: life year gained; QALY: quality adjusted life year
gained.
https://doi.org/10.1371/journal.pone.0172864.t005
Fig 2. Efficient frontiers for different levels of colonoscopy capacity. Costs and QALYs gained per 1,000
participants, compared to no screening. QALY: quality adjusted life year; gFOBT: guaiac fecal occult blood test; FIT: fecal
immunochemical test; Col/year: number of colonoscopies required per 1,000 participants per year. Strategies are varying
by age at starting screening, age at stopping screening, screening interval, and FIT cut-off level. For each level of available
colonoscopy capacity (maximal 17, 20, 30, 40 colonoscopies per 1,000 participants per year and unrestricted colonoscopy
capacity) the cost-effective strategies are connected by their respective efficient frontier. The text boxes beside each
frontier present the screening strategy (test, age range, interval and colonoscopy
https://doi.org/10.1371/journal.pone.0172864.g002
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for CRC treatment. GFOBT mainly detects CRC. While early detection of CRC is associated
with a reduction in CRC mortality, the costs of CRC treatment are not substantially reduced.
On the other hand FIT, even at the cut-off level of 200 ng Hb/ml, is more than twice as sensi-
tive for large adenomas than gFOBT,[24] and is associated with prevention of more CRC and
associated treatments. At the 200 cut-off level, the specificity of FIT is similar to gFOBT result-
ing in similar colonoscopy demand.[24]
Most previous cost-effectiveness analyses found FIT screening to be cost-effective, but FIT
was generally also more costly than gFOBT.[32, 36–41] However, most studies used what are
now outdated estimates of CRC treatment costs[42] and considered a single, or a limited num-
ber of screening strategies. Our findings are in line with the study by Heitman et al. which
reported FIT screening to be more effective and less costly than gFOBT.[43] Heitman et al.
used an indirect method to estimate current CRC treatment costs in Canada. In our analysis
we used recent CRC treatment data as observed with a fully allocated costing approach and
included costs of recently introduced biologic therapies (manuscript in preparation).
Our study adds to the study of Heitman et al in several ways. First, multiple models corrob-
orating the same conclusion strengthen the confidence in that conclusion, especially when the
models differ in their structure for the natural history of CRC (e.g. MISCAN assumes sensitiv-
ity of FIT to depend on time to clinical diagnosis and assumes improved prognosis of screen-
detected cancers vs clinically diagnosed cancers). Second, we explored a much wider range of
gFOBT and FIT screening strategies than Heitman (different start and stop age, screening
intervals and FIT cut-off level). This analysis shows that FIT is always the preferred strategy
across this whole range of strategies, but more importantly this approach allows selection of
the optimal strategy for Ontario. In addition, we considered different levels of available colo-
noscopy capacity to see if FIT would still be the preferred strategy if colonoscopy capacity is
limited. Our results clearly indicate that even at lower colonoscopy capacity levels, it is still
most efficient to use FIT-based screening, albeit at higher cut-offs.
Our study should be interpreted in light of its strengths and limitations. First, there is con-
siderable uncertainty in assumptions used in the model. Several assumptions could not be
directly estimated using Canadian information and were therefore based on international
data. We evaluated the impact of uncertainty on several parameters in one-way sensitivity
analyses and found that our results were robust to these assumptions. One of the most uncer-
tain assumptions is that all CRCs arise from adenoma precursors. We considered a sensitivity
analysis with the assumption that 74% of large adenomas did not bleed (and were therefore
undetectable) by gFOBT and FIT[33], which did not greatly affect the relative cost-effective-
ness of FIT compared to gFOBT. We did not perform a probabilistic sensitivity analysis. Given
the large number of strategies that would need to be evaluated, such an analysis would require
a huge computational effort. We prioritized the large number of strategies over the probabilis-
tic sensitivity analysis, because we were primarily interested in the comparison between differ-
ent gFOBT and FIT screening strategies allowing for varying screening age ranges, intervals
and FIT cut-off levels. Given the similar nature of gFOBT and FIT screening, many uncertain-
ties in model parameters influence both gFOBT and FIT in a similar way and will therefore
not influence the comparative effectiveness of FIT versus gFOBT. The difference in perfor-
mance between both tests is mainly driven by the differences in test characteristics for which
there is very convincing evidence that FIT outperforms gFOBT screening from several studies.
[24, 26] This is also the reason that it is the preferred method of screening according to the
European guidelines.[44] We therefore don’t expect that the conclusions of this study would
change if we had performed a probabilistic sensitivity analysis.
Second, we assumed perfect adherence to screening, follow-up and surveillance, in order to
represent the cost-effectiveness for participants who follow program recommendations. On a
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population level, screening adherence will be less than 100%, which will impact the cost-effec-
tiveness ratios. However, it has been demonstrated that adherence to FIT is greater than to
gFOBT screening.[25, 26] Therefore the difference in cost-effectiveness between the two tests
is likely to be even greater when screening adherence is taken into account.
Finally, we did not explicitly model distinct pathways for traditional and sessile serrated
adenomas. The average time it takes for an adenoma to develop into CRC was calibrated to the
UK flexible sigmoidoscopy screening trial which included both traditional and sessile serrated
adenomas. Both adenoma types are therefore included in the modelled mix of slow and rapid
progressing lesions. Our conclusion would only be influenced by not explicitly modeling the
serrated polyp pathway if the sensitivity for serrated adenomas would differ between FIT and
gFOBT and these lesions would have higher malignant potential than adenomas in general.
Limited evidence suggests that FIT might be less sensitive for serrated polyps than for adeno-
mas, because they are often flat and therefore less likely to bleed. However, given the similar
nature of gFOBT, this test is expected to be affected similarly.
This study has been performed in the setting of the ColonCancerCheck program in
Ontario, Canada. In addition to Ontario, there are a number of regions around the world that
use gFOBT in their CRC screening programs.[5, 6] Provided that the relative difference
between the costs of screening tests and CRC treatment is not radically different from Ontario,
the results from this study can be generalized to these other jurisdictions.
In conclusion, we found FIT to be more effective and less costly than gFOBT screening in
average risk individuals for a wide range of screening strategies. This conclusion was robust to
a wide range of assumptions. The optimal FIT strategy depends on the available colonoscopy
capacity. Compared to gFOBT screening, introducing FIT at a high cut-off level could increase
the health benefits of a CRC screening program without considerably increasing colonoscopy
demand.
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